Ionis Pharmaceuticals IONS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's total current liabilities?
- Ionis Pharmaceuticals (IONS) reported total current liabilities of $716.59M in Q1 2026.
- How has Ionis Pharmaceuticals's total current liabilities changed year-over-year?
- Ionis Pharmaceuticals's total current liabilities increased by 186.3% year-over-year, from $250.29M to $716.59M.
- What is the long-term trend for Ionis Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's total current liabilities has grown at a 5.5% compound annual growth rate (CAGR), from $598.9M to $781.57M.
- What does total current liabilities mean?
- The total amount of all debts and obligations due within one year.
- How do you interpret total current liabilities?
- A rising trend relative to current assets may signal liquidity pressure, whereas a stable or declining trend suggests effective management of short-term obligations.
- How does total current liabilities compare across companies?
- Standardized across all industries; peers in biotech often maintain higher levels during intensive clinical trial phases.